Exploring The Alarming Surge Of Life Threatening Events Linked To Mavacamten- Analysis Of FDA Adverse Event Reporting System Database
Resha Khanal,Kripa Rajak,Rajendra Shah,Anupam Halder,Kriti Kalra,Saman Razzaq,Binita Bhandari,Sristee Niraula,Shital Oli,Sharad Oli
DOI: https://doi.org/10.1016/j.cardfail.2023.10.246
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:Background Mavacamten is a novel cardiac myosin ATPase inhibitor targeted for treatment of hypertrophic obstructive cardiomyopathy (HOCM). It acts by formation of actin-myosin cross-bridge thus reducing contractility and improving myocardial energetics. Since its approval in April 2022 by the U.S. Food and Drug Administration (FDA), it has been popular for treatment of patients with symptomatic New York Heart Association (NYHA) class II-III HOCM. During review by FDA, mavacamten exhibited a side effect profile of heart failure (HF) that was deemed significant enough to warrant as a boxed warning. Therefore, it is of utmost importance to establish a comprehensive post-marketing safety profile of this drug in the general population since the EXPLORER-HCM phase 3 clinical trial. Methods We investigated the reported Adverse Events (AEs) of mavacamten using FDA Adverse Event Reporting System (FAERS). A total of 389 AEs were reported until December 31st, 2022; out of which 51.67% were reported by healthcare professionals (HCPs). We conducted further analysis of AEs in male (24.88%) versus females (51.24%) as well as in three age groups: 18-64, 65-85 and > 85 years. Results Amongst the AEs reported by HCPs, a total of 87 (43.36%) events were life-threatening events which included 2.99% hospitalization and 1.99% death. AEs were mostly reported in the age group of 65-85 years (31.34%). The most frequently reported AEs was HF (12.45%) followed by atrial fibrillation (A.fib) (9.45%), dyspnea (7.96%), dizziness (6.47%), fatigue (5.97%), and syncope (3.98%). Amongst females, dyspnea (9.71%) was most reported AEs whereas A.fib (18%) was the most reported AEs in male patients. Discussion: The reported events of HF were significantly higher (12.45%) in FAERS reporting as compared to the EXPLORER-HCM trial (6%). However, normalization of ejection fraction was seen in the trial with discontinuation of the medication. After conducting a thorough analysis, we have noticed a surge in the frequency of reported life-threatening events including heart failure, atrial fibrillation, dyspnea, and others which could be attributed to drug-induced reduced systolic contraction. Nevertheless, the extent of reversibility and potential long-term effects of these events remain uncertain. Conclusion Given the growing utilization of mavacamten, it is imperative to conduct additional randomized controlled trials to gain a better understanding of its safety profile.
cardiac & cardiovascular systems